Earlier this year we reported on the Federal Trade Commission’s efforts taken against certain drug manufacturers when listing device patents in the FDA’s Orange Book. We concluded that the efforts to date by the FTC had a minimal impact on a manufacturer’s decision on whether to list a device patent….
By: Polsinelli
By: Polsinelli
